Bibliographic record

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind…

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. The Lancet Diabetes & Endocrinology 2024

§1Bibliographic record

Authors: le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM
Title: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Source: The Lancet Diabetes & Endocrinology
Year: 2024
Volume, issue, pages: 12(3):162–173
Digital object identifier: 10.1016/S2213-8587(23)00356-X
PubMed identifier: 38330977
Record type: Journal article
Institute identifier: CEI-BR-066

Table 1. Documents in the Institute set that cite this record.

Document	Series
Monograph: Survodutide	Compound monograph
Monograph: Mazdutide	Compound monograph
Synthesis: Survodutide in obesity and overweight in adults: effect on the anchor…	Evidence synthesis
Synthesis: Mazdutide in obesity and overweight in adults: effect on the anchor…	Evidence synthesis
Synthesis: Mazdutide in type 2 diabetes mellitus: effect on the anchor outcome	Evidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: tolerability and…	Evidence synthesis
Synthesis: Mazdutide in obesity and overweight in adults: tolerability and…	Evidence synthesis
Synthesis: Mazdutide in type 2 diabetes mellitus: tolerability and…	Evidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: durability of effect	Evidence synthesis
Synthesis: Mazdutide in obesity and overweight in adults: durability of effect	Evidence synthesis
Synthesis: Mazdutide in type 2 diabetes mellitus: durability of effect	Evidence synthesis
11 citing documents.

survodutide obesity

Compound Evidence Institute · CEI-BR-066 · https://compoundevidence.com/bibliography/leroux2024/ · retrieved 30 July 2026